has been cited by the following article(s):
|
[1]
|
Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis
Gynecologic Oncology,
2021
DOI:10.1016/j.ygyno.2021.03.002
|
|
|
|
|
[2]
|
Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis
Gynecologic Oncology,
2021
DOI:10.1016/j.ygyno.2021.03.002
|
|
|
|
|
[3]
|
Uterine Cervical Cancer
2019
DOI:10.1007/978-3-030-02701-8_11
|
|
|
|
|
[4]
|
The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer
Medicine,
2018
DOI:10.1097/MD.0000000000010340
|
|
|
|
|
[5]
|
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
Critical Reviews in Oncology/Hematology,
2016
DOI:10.1016/j.critrevonc.2016.11.006
|
|
|
|